Eliem Therapeutics Names New Directors, Updates Exec Pay
Ticker: CLYM · Form: 8-K · Filed: Aug 26, 2024 · CIK: 1768446
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
Eliem adds two directors and updates CEO/CMO employment deals.
AI Summary
Eliem Therapeutics, Inc. announced on August 26, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. Jeffrey W. Allen and Ms. Sarah L. Kelly, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Andrew A. von Eschenbach, and its Chief Medical Officer, Dr. Robert J. Davies, effective August 26, 2024.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and executive compensation updates, which are common and do not indicate significant operational or financial distress.
Key Players & Entities
- Eliem Therapeutics, Inc. (company) — Registrant
- Dr. Jeffrey W. Allen (person) — Newly elected Director
- Ms. Sarah L. Kelly (person) — Newly elected Director
- Dr. Andrew A. von Eschenbach (person) — Chief Executive Officer
- Dr. Robert J. Davies (person) — Chief Medical Officer
- August 26, 2024 (date) — Effective date of changes
FAQ
Who were the new directors elected to Eliem Therapeutics' Board?
Dr. Jeffrey W. Allen and Ms. Sarah L. Kelly were elected as new directors.
What is the effective date for the new employment agreements?
The new employment agreements for the CEO and CMO are effective August 26, 2024.
What specific items are covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
What is Eliem Therapeutics, Inc.'s state of incorporation?
Eliem Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Eliem Therapeutics?
The principal executive office is located at 2801 Centerville Road, 1st Floor, PMB #117, Wilmington, DE 19808-1609.
Filing Stats: 1,486 words · 6 min read · ~5 pages · Grade level 10.5 · Accepted 2024-08-26 07:07:00
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ELYM The Nasdaq Stock Mar
- $500,000 — r. Kaplan will be paid a base salary of $500,000 per year. Dr. Kaplan will also be eligi
Filing Documents
- d866047d8k.htm (8-K) — 33KB
- d866047dex101.htm (EX-10.1) — 62KB
- g866047g0823073604553.jpg (GRAPHIC) — 5KB
- 0001193125-24-206655.txt ( ) — 243KB
- elym-20240826.xsd (EX-101.SCH) — 3KB
- elym-20240826_lab.xml (EX-101.LAB) — 18KB
- elym-20240826_pre.xml (EX-101.PRE) — 11KB
- d866047d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Offer Letter, dated July 31, 2024, between Eliem Therapeutics, Inc. and Brett Kaplan, M.D. 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Eliem Therapeutics, Inc. Date: August 26, 2024 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer